Shannon Baumann currently serves as the Head of Value and Access for the Neuromuscular Franchise at Biogen, a position held since October 2022. Previously, Shannon was the Vice President of Access, Value, and Evidence Strategy at bluebird bio, leading global access and value strategies for rare diseases from June 2016 to April 2022. Other roles at Biogen included Senior Director and Director of Global Market Access, where Shannon focused on pricing and reimbursement strategies from June 2012 to May 2016. Earlier career experiences include positions at Charles River Associates and Caro Research, along with consultancy roles at Cambridge Finance Partners, LLC. Shannon holds an MSc in Health Economics from The London School of Economics and Political Science and a BA in Economics and Mathematics from Boston College.
This person is not in any teams
This person is not in any offices